Valuation : Gilead Sciences, Inc.

Market Cap 18TCr 2,73,41200Cr 16TCr 15TCr 13TCr 25TCr 17,26400Cr 25TCr 1,73100Cr 68TCr 8,71500Cr 68TCr 66TCr 28,89700Cr P/E 2026 *
-44.5x
P/E 2027 * 18.2x
Enterprise Value 20TCr 2,98,75700Cr 17TCr 16TCr 15TCr 27TCr 18,86500Cr 28TCr 1,89200Cr 74TCr 9,52300Cr 74TCr 72TCr 31,57600Cr EV / Sales 2026 *
6.43x
EV / Sales 2027 * 5.8x
Free-Float
99.88%
Yield 2026 *
2.26%
Yield 2027 * 2.33%
1 day-1.85%
1 week+0.47%
Current month+13.61%
1 month+14.39%
3 months+17.23%
6 months+6.47%
Current year+24.68%
1 week 58,175
Extreme 58175
59,975
1 month 50,825
Extreme 50825
59,975
Current year 44,320
Extreme 44320
59,975
1 year 36,450
Extreme 36450
59,975
3 years 13,722
Extreme 13722
59,975
5 years 2,682.5
Extreme 2682.5
59,975
10 years 656.5
Extreme 656.5
59,975
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
-1.85%+0.47% - - 18TCr
-0.13%-6.44%+60.34%+114.35% 1,04700Cr
+0.85%-0.81%+51.29%+63.71% 65TCr
-1.03%-3.58%+21.43%+72.25% 45TCr
-0.49%-3.62%+37.20%+37.15% 35TCr
+0.02%-2.40%+21.84%+38.53% 29TCr
-1.19%-2.21%+1.53%+11.51% 25TCr
-1.05%-1.57%+50.30%+67.68% 23TCr
-0.86%-2.12%-19.78%-54.02% 20TCr
-2.14%-0.30%+28.95%+87.59% 18TCr
Average -0.79%-2.68%+28.12%+48.75% 40.66TCr
Weighted average by Cap. -0.43%-3.46%+37.96%+65.99%

Financials

2026 *2027 *
Net sales 3.07TCr 46,45600Cr 2.64TCr 2.48TCr 2.26TCr 4.26TCr 2,93300Cr 4.28TCr 29TCr 11TCr 1,48100Cr 12TCr 11TCr 4,91000Cr 3.27TCr 49,48700Cr 2.82TCr 2.64TCr 2.41TCr 4.54TCr 3,12500Cr 4.56TCr 31TCr 12TCr 1,57700Cr 12TCr 12TCr 5,23000Cr
Net income -427.47Cr -6,47000Cr -368.35Cr -345.37Cr -315.27Cr -593.92Cr -41TCr -595.81Cr -4.1TCr -1.6TCr -21TCr -1.6TCr -1.57TCr -68TCr 1.03TCr 15,55200Cr 885.4Cr 830.15Cr 757.8Cr 1.43TCr 98TCr 1.43TCr 9.85TCr 3.84TCr 50TCr 3.86TCr 3.77TCr 1,64400Cr
Net Debt 1.67TCr 25,34600Cr 1.44TCr 1.35TCr 1.23TCr 2.33TCr 1,60000Cr 2.33TCr 16TCr 6.26TCr 81TCr 6.29TCr 6.15TCr 2,67900Cr 912.45Cr 13,81100Cr 786.26Cr 737.2Cr 672.95Cr 1.27TCr 87TCr 1.27TCr 8.75TCr 3.41TCr 44TCr 3.43TCr 3.35TCr 1,46000Cr
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
28/26/28 ARS 58,425.00 -1.85% 1,882
27/26/27 ARS 59,525.00 0.00% 334
26/26/26 ARS 59,525.00 +0.04% 540
25/26/25 ARS 59,500.00 +1.54% 480
24/26/24 ARS 58,600.00 +0.77% 1,467
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
145.68USD
Average target price
157.41USD
Spread / Average Target
+8.05%

Quarterly revenue - Rate of surprise